A significant trend is emerging in pediatric sleep clinics: a substantial number of children presenting with sleep difficulties have either used or are currently using melatonin. While melatonin is recognized as a valuable therapeutic tool for certain childhood sleep disorders and is often perceived as safe due to its natural origin, a growing concern centers on its widespread and sometimes unsupervised use. This trend mirrors a broader societal shift, with studies indicating a dramatic increase in melatonin consumption among adults as well. The aggressive marketing of children’s melatonin products further exacerbates these concerns, leading to a perception that it may be used as a facile solution, bypassing the establishment of robust sleep hygiene practices.
Recent data from a 2022 JAMA study revealed that adult melatonin use had tripled between 2005 and 2018, with individuals also increasing their dosage. This escalation in adult usage provides a potential precursor to understanding the current landscape of pediatric melatonin consumption. While precise figures for children remain elusive, a 2020 New York Times article highlighted an 87% surge in overall melatonin sales in the year preceding March 2020. A survey conducted for that article indicated that over half of parents with children under 18 had administered melatonin to their children at some point, with one-third reporting past-year sleep difficulties. More recent global trends underscore the increasing reliance on melatonin, with Scandinavia experiencing a nearly 500% rise in prescriptions. In the United States, melatonin has become the most frequent cause of overdose incidents in pediatric emergency rooms and a leading reason for calls to poison control centers, signaling a worldwide issue that warrants careful examination.
Understanding Melatonin: A Hormonal Regulator
Melatonin is a hormone naturally produced by the pineal gland in the brain. It functions as a chronobiotic agent, meaning it plays a crucial role in regulating the body’s circadian rhythm, or internal clock. At higher doses, it can also exhibit hypnotic effects, inducing sleep. However, it is important to distinguish between these two functions: while the chronobiotic effect is present in all individuals, the hypnotic effect is not universally experienced.
The natural release of melatonin in the body typically begins one to three hours before sleep onset, a phenomenon known as the "dim light melatonin onset" (DLMO). This biological signal helps to schedule sleep and marks the decline of the body’s wakefulness signals. For children experiencing insomnia, melatonin is sometimes administered after their scheduled bedtime has passed, suggesting their bodies are not yet biologically ready for sleep. This physiological timing is one reason why behavioral interventions like "bedtime fading" can be effective. Clinical doses of melatonin, often ranging from 0.5 mg to 10 mg or higher, significantly exceed the amounts naturally secreted by the body.
Effectiveness of Melatonin in Pediatric Sleep Disorders
The reported benefits of melatonin for children’s sleep issues include a reduction in the time it takes to fall asleep and an increase in overall sleep duration. However, the scientific literature on its efficacy in children is still relatively limited. Many studies involve small participant groups and are conducted over short durations. A significant factor contributing to this data gap is that melatonin is regulated as a dietary supplement by the U.S. Food and Drug Administration (FDA), rather than as a pharmaceutical. This regulatory classification means that large-scale, long-term safety and efficacy studies, often bankrolled by pharmaceutical companies for prescription medications, are not typically conducted for melatonin.
A comprehensive review by the International Pediatric Sleep Association (IPSA) provides valuable insights, including dosing recommendations and literature reviews for both typically developing children and those with autism spectrum disorder. The overarching finding across numerous studies suggests that melatonin can provide approximately 30 minutes of additional sleep per night, primarily by shortening the time it takes to fall asleep. While this effect is consistent, it’s crucial to recognize that melatonin is not a panacea for sleep problems.
Chronic Sleep Onset Insomnia in Typically Developing Children
Difficulty falling asleep is a prevalent issue among children, akin to adult insomnia. Chronic insomnia is characterized by persistent challenges with initiating or maintaining sleep at least three times per week for three months or more, leading to significant distress or impairment in daytime functioning. A 2023 meta-analysis by Edemann-Callesen, which synthesized data from 419 children, indicated an approximate 30-minute increase in total sleep time, with about 18 minutes attributed to a reduction in sleep latency (time to fall asleep). Notably, this meta-analysis did not find improvements in daytime functioning and did report an increase in adverse events among children receiving melatonin compared to those in the placebo group.
The 2025 IPSA position paper on melatonin for typically developing children offers specific recommendations for this demographic, emphasizing a cautious and evidence-based approach to its use.
Melatonin and Autism Spectrum Disorder (ASD)
Sleep disturbances are particularly common in children with autism spectrum disorder (ASD). These issues can manifest as prolonged sleep onset latency, reduced total sleep time, and frequent awakenings during the night or early morning. Some research suggests that children with ASD may have lower baseline levels of melatonin and less diurnal variation in its secretion. Consequently, melatonin has been frequently employed in this population, often leading to improved sleep onset and duration. Studies have utilized both immediate-release and long-acting formulations, typically administered 30-60 minutes before bedtime.
A 2025 meta-analysis by Yang et al. identified that the most significant benefits of melatonin in children with ASD were observed in sleep efficiency (the ratio of time asleep to time in bed) and total sleep time, rather than sleep latency. The study also noted that the effectiveness of melatonin was more pronounced in older children and that its benefits could diminish over time. Higher doses appeared to be more efficacious than lower doses.
A 2017 trial investigating a time-released melatonin preparation, PedPRM, at doses of 2-5 mg, found that children experienced an average of 57.5 minutes more sleep compared to a control group. The primary driver of this benefit was a reduction in sleep latency, with treated children falling asleep approximately 39 minutes faster. While this medication, branded as Slenyto in Europe, is not currently approved by the FDA for use in the U.S., its research provides valuable data.
The 2024 IPSA recommendations for melatonin use in ASD highlight the importance of integrating melatonin with behavioral management strategies. A 2020 guideline from the American Academy of Neurology also advocates for addressing behavioral issues first, then considering melatonin, and potentially exploring long-acting formulations if necessary, with dosages typically starting at 2 mg and gradually increasing to a maximum of 10 mg. These guidelines consistently recommend that melatonin should be an adjunct to a comprehensive behavioral management plan. Resources like the Autism Speaks Sleep Toolkit and the book "Solving Sleep Problems in Children with Autism Spectrum Disorders: A Guide for Frazzled Families" offer further support for families navigating these challenges.
Melatonin and Attention Deficit Hyperactivity Disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is frequently accompanied by sleep disturbances, and conversely, sleep problems can exacerbate ADHD symptoms. Historical observations, dating back to early descriptions of the "hyperkinetic behavior syndrome," noted the profound impact of nighttime sleep issues on families, often overshadowing daytime behavioral concerns. Studies suggest that up to 70% of children with ADHD may experience sleep problems, including difficulty falling asleep, altered sleep architecture, and daytime sleepiness.
A 2024 review by Cortese on sleep management in ADHD highlighted two randomized controlled trials demonstrating positive effects. A 2024 systematic review by Larsson indicated a 30-minute decrease in sleep latency and improved sleep efficiency, though it found no evidence of improvements in quality of life or daytime ADHD symptoms. A small trial suggested that melatonin could help with insomnia in children with ADHD taking stimulant medication, but this finding was based on chart review and requires further validation.
Delayed Sleep Phase Syndrome (DSPS) and Melatonin
Delayed sleep phase syndrome (DSPS) is a common disorder among adolescents, characterized by a significant shift in their natural sleep-wake cycle to later times, often making it impossible to fall asleep before 1-2 AM or later. This misalignment with school schedules can lead to chronic sleep deprivation. Melatonin plays a well-established role in managing DSPS. Administering low doses several hours before the desired sleep onset, in conjunction with light exposure management, sleep hygiene practices, and gradual schedule adjustments (chronotherapy), can effectively shift sleep periods earlier. The underlying cause in DSPS is a delayed DLMO, which melatonin can help to advance. For children with DSPS, a dose is typically given 4-6 hours before their current usual sleep onset time, with gradual advancement every 4-5 days. Among the conditions discussed, DSPS demonstrates the clearest and most consistent benefit from melatonin therapy.
Children with Neurodevelopmental Delay and Blindness
Children with various forms of neurodevelopmental delay may experience significant insomnia, and melatonin can be a beneficial treatment option. However, in some instances, melatonin use has been associated with persistently elevated daytime melatonin levels and subsequent daytime sleepiness. A 2023 review by Edemann-Callesen examined melatonin’s effects in a mixed group of conditions, including those with neurodevelopmental delays, reporting a modest increase in total sleep time (primarily due to reduced latency) but no significant improvements in subjective sleep quality or daytime functioning.
For children with blindness, the absence of light cues can disrupt circadian rhythms, leading to sleep-wake cycle disorders. While limited studies, primarily in adults, suggest potential benefits, the data specifically for children with blindness and sleep issues remains very restricted.
Eczema and Melatonin
Eczema, a condition characterized by dry, itchy skin, is often associated with sleep disturbances, including insomnia and non-restorative sleep. Some research suggests that children with eczema may have lower melatonin levels, and preliminary trials indicate that melatonin supplementation could be helpful in improving sleep for these children.
Concerns Regarding Melatonin Use in Children
Despite its perceived benefits, several concerns warrant careful consideration regarding melatonin use in children. These include potential side effects, theoretical risks, and issues with product quality and labeling.
Theoretical Side Effects: One theoretical concern is that prolonged melatonin administration could lead to persistently elevated blood melatonin levels throughout the day, potentially causing daytime sleepiness. However, the long-term effects of such elevations are not fully understood. It is critical to reiterate that melatonin has not undergone the rigorous testing typically required for pharmaceutical drugs. Long-term safety studies in children have largely relied on parental reports, with less emphasis on biochemical confirmation. Dr. David Kennaway, a physician from Australia, has published editorials highlighting the inadequacy of long-term safety data for melatonin in children, notably pointing out that it is a registered veterinary drug used to alter reproduction in sheep and goats. This underscores the need for greater caution and more comprehensive research.
Product Quality and Labeling: A significant concern lies in the regulatory oversight of melatonin as a dietary supplement. This means that the manufacturing processes and quality control are not as stringent as those for pharmaceuticals, leading to variability in product purity and potency. Furthermore, product labeling can be misleading. For example, a liquid melatonin preparation labeled as "1 mg" might actually contain only 0.25 mg per dropperful, requiring parents to consult online resources or package inserts for accurate dosing information, which are often overlooked. This lack of clear and standardized labeling increases the risk of incorrect dosing.
A 2020 study that followed 80 children using the long-acting melatonin formulation PedPRM for two years found no evidence of adverse effects on weight, height, body mass index, or sexual development. While this study offers some reassurance regarding long-term safety, the call for more extensive long-term research persists.
Addressing Concerns for Families
For parents whose children are already taking melatonin, it is not cause for immediate alarm. However, if melatonin was initiated without physician consultation, it is strongly advised to discuss its necessity with the child’s pediatrician. If a child has been using melatonin long-term and is sleeping well, a gradual dose reduction can be considered to assess continued need. Encouraging "as-needed" use rather than nightly administration is also a prudent approach. A thorough review of sleep hygiene practices, including a consistent and high-quality bedtime routine and avoidance of screen time for at least an hour before bed, is paramount. The IPSA guidelines suggest limiting melatonin use to 3-6 months and periodically attempting to discontinue it.
Given the rise in melatonin overdoses, ensuring that melatonin is stored safely and dosed accurately is crucial. Parents should also be aware of potential interactions with other medications.
Optimizing Melatonin Use Under Medical Guidance
When melatonin is considered under the guidance of a healthcare professional, several factors are important:
Timing of Administration: Melatonin’s effectiveness is highly dependent on its timing relative to the child’s natural sleep schedule. A small dose administered a few hours before bedtime can be more impactful than a larger dose given at bedtime. Generally, 30-60 minutes prior to bedtime is considered optimal, though earlier administration may be beneficial in some cases.
Dosing Recommendations: The 2025 IPSA guidelines provide age-based dosing recommendations, suggesting starting at 0.5 mg and increasing weekly by 0.5 mg until improvement is observed or the maximum dose is reached. A melatonin dosing calculator, developed based on current guidelines, can assist parents and physicians in selecting the safest appropriate dose for their child.
Crucially, melatonin should never be viewed as a substitute for robust sleep hygiene practices. It must be integrated with a high-quality bedtime routine, appropriate light exposure management, and a consistent sleep schedule. When possible, selecting products with USP Verified status can provide an added layer of assurance regarding manufacturing quality and ingredient accuracy.
Conclusion: A Balanced Approach to Pediatric Sleep
The decision to use melatonin for a child’s sleep issues is often made after considerable deliberation and following unsuccessful attempts at behavioral interventions. With limited FDA-approved insomnia medications for children, melatonin has become a common tool for many pediatricians. While acknowledging the concerns raised by experts regarding its long-term safety and regulatory status, the tangible benefits of improved sleep for children and their families cannot be overlooked. Pediatricians aim to minimize medication use and explore all avenues to address insomnia, including investigating other underlying causes like restless leg syndrome. For children with conditions such as autism or developmental delays, where sleep disturbances are often more profound, melatonin may be a necessary and effective option. The overarching goal remains to help children achieve restful sleep with the least amount of intervention necessary, a shared objective for both healthcare providers and parents. It is also important to consider that sudden sleep difficulties may indicate a sleep regression, for which specific strategies can be employed.
